MTOR and epilepsy: TSC represents a prototypic monogenic disorder of the mTOR pathway dysregulation establishing mechanistic basis of a direct link between genetic variants and brain pathology underlying intractable epilepsy.[2] Several studies have addressed the cellular and molecular pathways that contribute to epileptogenesis, with the aim to develop targeted therapies to effectively prevent or halt this process.[1] However, the clinical efficacy of rapamycin has been limited.